13F filer · CIK 1637359
Omega Fund Management, LLC
Boston, MA · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$185.7M
+$22.5M vs prior
Positions
10
New / sold out
1 / 1
Added / reduced
0 / 1
Turnover
0.0%
buys $54.1K · sells $18.8M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Odyssey Therapeutics Inc. | +2,893 | – | +$54.1K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Bicara Therapeutics Inc. | -570,000 | -23.8% | $-16.9M |
| Sold out | Replimune Group | -248,672 | -100.0% | $-1.9M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc.COMMON STOCK | 1,822,150 | $54.1M | 29.14% |
| 2 | Nuvation Bio Inc.COMMON STOCK CLASS A | 8,081,089 | $45.9M | 24.72% |
| 3 | Kestra Med Technologies LtdCOMMON STOCK | 1,022,149 | $26.0M | 14.00% |
| 4 | BridgeBio Oncology Therapeutics Inc.COMMON STOCK | 3,289,661 | $25.1M | 13.50% |
| 5 | Beta Bionics Inc.COMMON STOCK | 1,316,183 | $20.6M | 11.11% |
| 6 | Alumis Inc.COMMON STOCK | 241,255 | $6.8M | 3.66% |
| 7 | Sana Biotechnology, Inc.COMMON STOCK | 843,750 | $2.9M | 1.59% |
| 8 | ImageneBio, Inc.COMMON STOCK | 455,361 | $2.7M | 1.45% |
| 9 | enGene Holdings Inc.COMMON STOCK | 876,357 | $1.5M | 0.82% |
| 10 | Odyssey Therapeutics Inc.COMMON STOCK | 2,893 | $54.1K | 0.03% |